<DOC>
	<DOCNO>NCT02404584</DOCNO>
	<brief_summary>The primary objective study determine percentage patient plasma concentration sunitinib remain equilibrium ( [ Suni ] REq ) great 100 ng / ml ( effective concentration accord current literature ) .</brief_summary>
	<brief_title>The Pharmacokinetic Variability Sunitinib Patients With Metastatic Renal Cancer</brief_title>
	<detailed_description>The secondary objective study : - To describe distribution constitutional genetic determinant relate sunitinib pharmacokinetics , study correlation - [ Suni ] REq , - advent toxicity , - tumor response . - To describe variation [ Suni ] REq plasma concentration active entity remain equilibrium ( [ ActEnt ] REq ) : - interindividual level , - overtime , chemotherapy cycle . - To describe variation ratio plasma concentration metabolite remain equilibrium ( [ Metab ] REq ) [ Suni ] REq : - interindividual level , - overtime , chemotherapy cycle . - To explore potential correlation [ Suni ] REq - toxicity , - tumor response . - To explore potential correlation [ ActEnt ] REq - toxicity , - tumor response . - To explore potential correlation ratio [ Metab ] REq / [ Suni ] REq - toxicity , - tumor response .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>The patient correctly inform concern implementation study , objective , constraint patient right The patient must give his/her inform sign consent The patient must insure beneficiary health insurance plan The patient kidney cancer begin treatment sunitinib ( Sutent ) time inclusion The patient start treatment sunitinib ( Sutent ) inclusion The patient participate another interventional study The patient participate another interventional study within last month The patient exclusion period determine previous study The patient judicial protection , tutorship curatorship The patient refuse sign consent It impossible correctly inform patient The patient pregnant , parturient , breastfeed The patient contraindication ( incompatible drug combination ) treatment use study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Metastatic kidney cancer</keyword>
</DOC>